TY - JOUR
TI - Hodgkin's disease in a child with sickle cell disease treated with
hydroxyurea
AU - Moschovi, M
AU - Psychou, F
AU - Menegas, D
AU - Tsangaris, GT and
AU - Tzortzatou-Stathopoulou, F
AU - Nikolaidou, P
JO - Pediatric Hematology and Oncology
PY - 2001
VL - 18
TODO - 6
SP - 371-376
PB - TAYLOR & FRANCIS LTD LONDON
SN - 0888-0018, 1521-0669
TODO - 10.1080/088800101316921985
TODO - childhood; Hodgkin’s disease; hydroxyurea; sickle cell disease
TODO - Hydroxyurea (HU) is an oral drug that ameliorates the clinical course
of,sickle cell anemia by increasing the levels of fetal hemoglobin and
decreasing the adhesion of red cells to endothelium. Although HU has
minimal short-term toxicity, few data are available about the long-term
safety and the potential risk for carcinogenesis or leukemogenesis. An
8-year-old child with sickle cell/beta (0)-thalassemia who received HU
treatment for painful crises is described. Six months after the
initiation of the HU treatment he developed Hodgkin’s disease,
lymphocyte predominance subtype. Chemotherapy, induced a complete
remission. After discontinuation of chemotherapy the painful crises
recurred and bone marrow transplantation was decided at the age of 12
years. Two years after the bone marrow transplantation, the child is in
complete remission without painful crises. Although the authors suggest
that the development of Hodgkin’s disease is a coexisting event,
questions arise about the safely of HU treatment in childhood.
ER -